Ischemic Mimics in Cardio-Oncology: A Case of Post-Chemotherapy MINOCA
- Authors
-
-
hela ben turkia
regional hospital of Ben Arous
-
Raja Fadhel
-
Amira Bekir
-
Youssef Ebn Ebrahim
-
Syrine keskes
-
Sami Souissi
-
- Keywords:
- Myocardial Infarction with Non-Obstructive Coronary Arterie, Takotsubo Cardiomyopathy, Cardiotoxicity, Breast Neoplasms, ST Elevation Myocardial Infarction
- Abstract
-
Advances in neoadjuvant therapies for breast cancer have increased the incidence of acute cardiotoxicity, often presenting as a diagnostic challenge in the emergency setting. We report the case of a 35-year-old female with invasive breast carcinoma, currently receiving neoadjuvant chemotherapy, who presented with acute retrosternal chest pain and ST-segment elevation in the anterior leads. Initial laboratory findings revealed a massively elevated cardiac troponin I level (5,830.60 ng/L) and severe chemotherapy-induced neutropenia. Emergency coronary angiography demonstrated unobstructed epicardial coronary arteries, establishing a working diagnosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA). Subsequent transthoracic echocardiography revealed apical and periapical akinesia, a phenotype consistent with Takotsubo cardiomyopathy. In the context of active oncological treatment, the diagnostic crossover between stress-induced cardiomyopathy and therapy-related myocarditis, particularly immune checkpoint inhibitor-associated myocarditis is critical. While Takotsubo syndrome is primarily managed with supportive care, acute myocarditis mandates immediate cessation of antineoplastic agents and the initiation of high-dose corticosteroids. This creates a formidable therapeutic paradox in the setting of severe neutropenia, where systemic immunosuppression poses a high risk of life-threatening sepsis. This case underscores that in patients presenting with a STEMI-like MINOCA during chemotherapy, clinical and echocardiographic findings may be insufficient for differentiation. Early Cardiac Magnetic Resonance (CMR) imaging is the definitive arbiter required to distinguish between these entities. Accurate diagnosis is essential to balance the management of fulminant cardiovascular events with the safe continuation of life-saving oncological care.
- References
-
1. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229–361. doi:10.1093/eurheartj/ehac244 PubMed PMID: 36017568.
2. Fourth Universal Definition of Myocardial Infarction (2018) | Circulation [Internet]. [cited 2026 May 4]. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000617
3. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc Interv. 2016 Apr;87(5):E202-223. doi:10.1002/ccd.26379 PubMed PMID: 26756277.
4. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association | Circulation [Internet]. [cited 2026 May 4]. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000670
5. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio ALP, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017 Jan 14;38(3):143–53. doi:10.1093/eurheartj/ehw149 PubMed PMID: 28158518.
6. Yildiz M, Ashokprabhu N, Shewale A, Pico M, Henry TD, Quesada O. Myocardial infarction with non-obstructive coronary arteries (MINOCA). Front Cardiovasc Med. 2022;9:1032436. doi:10.3389/fcvm.2022.1032436 PubMed PMID: 36457805; PubMed Central PMCID: PMC9705379.
7. Boudiche S, Chedly M, Saadi M, Halima MB, Charfeddine S, Abid L, et al. Spontaneous coronary artery dissection cohort study: A nationwide Tunisian series. Tunis Med. 2026 Apr 12;104(03). doi:10.62438/tunismed.v104i03.6475
8. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy | New England Journal of Medicine [Internet]. [cited 2026 May 4]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1406761
9. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018 Jun 7;39(22):2032–46. doi:10.1093/eurheartj/ehy076 PubMed PMID: 29850871; PubMed Central PMCID: PMC5991216.
10. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal/intrathoracic cancer and radiation therapy. Int J Cardiol. 2020 Jun 15;309:14–8. doi:10.1016/j.ijcard.2020.02.036 PubMed PMID: 32087939.
11. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) - PubMed [Internet]. [cited 2026 May 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/27567406/
12. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020 Feb 27;382(9):810–21. doi:10.1056/NEJMoa1910549
13. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933. doi:10.1016/S0140-6736(18)30533-6 PubMed PMID: 29536852; PubMed Central PMCID: PMC6668330.
14. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020 Jan 21;9(2):e013757. doi:10.1161/JAHA.119.013757 PubMed PMID: 31960755; PubMed Central PMCID: PMC7033840.
15. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018 Dec 18;72(24):3158–76. doi:10.1016/j.jacc.2018.09.072 PubMed PMID: 30545455.
- Downloads
- Published
- 30-06-2026
- Section
- Case Reports
- License
-
Copyright (c) 2026 Tunisian Journal of Emergency Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
THE tjem allows authors to retain unrestricted copyright and full publishing rights of their articles.
All articles published in this journal are openly accessible and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This guarantees that anyone is free to:
-
Share: Copy and redistribute the material in any medium or format.
-
Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
Under the following terms:
-
Attribution: Users must give appropriate credit to the original author(s) and the journal, provide a link to the license, and indicate if changes were made.
By submitting a manuscript to tjem, authors grant the journal the right of first publication, while retaining full ownership of their intellectual property.
-
